1. Introduction {#sec1-cells-09-01141}
===============

Extracellular vesicles (EVs) are cell-released particles ranging in size from 30 to 1000 nm, enclosed within a phospholipid bilayer and which do not replicate. In addition to managing cellular waste, they play a pivotal role in mediating intercellular communication under both physiological and pathological conditions \[[@B1-cells-09-01141],[@B2-cells-09-01141],[@B3-cells-09-01141],[@B4-cells-09-01141]\]. EVs can vary in size, properties, and biological functions and are mostly classified as exosomes (30--120 nm in diameter), microvesicles (also known as MVs, ectosomes or microparticles, 100--1000 nm), or apoptotic bodies (ranging from 800 to 5000 nm) ([Figure 1](#cells-09-01141-f001){ref-type="fig"}a--c). Their classification depends on their biogenesis pathway. Exosomes are derived from the endolysosomal pathways, which involves inward budding in early endosomes, forming multivesicular bodies. Compared to other classes, exosomes seem to represent a more heterogeneous population of EVs. On the other hand, microvesicles are released via direct shedding from the plasma membrane. Finally, apoptotic bodies are formed during cytoskeletal rearrangement, being released by outward blebbing and decomposition of the cell membrane of apoptotic cells. Among them, apoptotic bodies are less frequently involved in intercellular communications \[[@B2-cells-09-01141],[@B5-cells-09-01141],[@B6-cells-09-01141]\].

EVs were originally reported in 1946 by Chargaff and West as procoagulant platelet-derived particles in normal plasma \[[@B7-cells-09-01141]\]. Later this observation was termed as ''platelet dust'' by Wolf in 1967 \[[@B8-cells-09-01141]\]. The confusion on the use of the right nomenclature arose from the lack of standardization of both isolation procedures and methods for the proper characterization of EV subgroups. Thus, it was only in 2011 that an important step was taken to unify the nomenclature and the methodologies for isolating EVs.

Indeed, given the difficulty in experimentally supporting the attribution of certain activities to EV subtypes, the absence of consensus in the nomenclature and the limited knowledge on their molecular mechanisms of biogenesis and release, recent guidelines from the International Society for Extracellular Vesicles (ISEV: [www.isev.org/](www.isev.org/)) were published. These guidelines advise researchers to refer to EVs by their physical characteristics (size and/or density), biochemical composition or descriptions of the cell of origin, unless their biogenesis pathway is confirmed, for example through live imaging techniques \[[@B1-cells-09-01141]\]. Therefore, in this review, we will use the widely adopted generic term "extracellular vesicles" (EVs) to refer to exosomes and/or microvesicles.

EVs are produced by almost all organisms and cell types and allow the intercellular transfer of molecules such as mRNAs, lipids, metabolites, proteins and non-coding RNAs (such as microRNAs and long non-coding RNAs), and even DNA fragments, which can induce phenotypic reprogramming of recipient cells \[[@B1-cells-09-01141],[@B2-cells-09-01141],[@B3-cells-09-01141],[@B4-cells-09-01141],[@B9-cells-09-01141],[@B10-cells-09-01141],[@B11-cells-09-01141],[@B12-cells-09-01141],[@B13-cells-09-01141],[@B14-cells-09-01141],[@B15-cells-09-01141]\] ([Figure 1](#cells-09-01141-f001){ref-type="fig"}d). Tumor-derived EVs have been shown to educate recipient cells towards a tumor-promoting phenotype, being involved in multiple steps of cancer development with roles in all cancer hallmarks. Tumor microenvironment (TME) may be altered by EVs, to support tumor growth and survival, induce angiogenesis, tumor cell invasion and metastasis, initiate resistance to cell death, evade immune response, reprogram cellular energy metabolism and drug resistance \[[@B3-cells-09-01141],[@B16-cells-09-01141],[@B17-cells-09-01141],[@B18-cells-09-01141],[@B19-cells-09-01141],[@B20-cells-09-01141]\].

EVs can be recovered from common body fluids, such as blood and plasma \[[@B21-cells-09-01141],[@B22-cells-09-01141]\], semen \[[@B23-cells-09-01141]\], urine \[[@B24-cells-09-01141]\], breast milk \[[@B25-cells-09-01141]\], nasal secretions \[[@B26-cells-09-01141]\], saliva \[[@B27-cells-09-01141]\], and even fecal matter \[[@B28-cells-09-01141]\] ([Figure 1](#cells-09-01141-f001){ref-type="fig"}e). Since their content reflects their cell of origin, EVs are attractive as potential biomarkers (or source of biomarkers) of certain malignancies, including cancer \[[@B2-cells-09-01141],[@B29-cells-09-01141],[@B30-cells-09-01141]\]. However, the heterogeneity of the EV populations within a biological sample might complicate such biomarker analysis, particularly since a single cell is capable of producing different subtypes of these vesicles \[[@B2-cells-09-01141],[@B31-cells-09-01141]\]. Furthermore, there is a lack of protocols to permit single EV analysis with a high degree of purity and specificity \[[@B1-cells-09-01141],[@B2-cells-09-01141]\].

EVs encapsulation of their cargo into a phospholipid bilayer provides this cargo with greater stability, a longer half-life, higher resistance to degradation, and a greater ability to travel long distances when compared to free proteins, lipids and nucleic acids in the cytoplasm. Moreover, EVs have the ability to transfer their cargo to recipient cells and organs that are protected by physiological barriers, such as the blood-brain barrier \[[@B32-cells-09-01141],[@B33-cells-09-01141],[@B34-cells-09-01141]\]. Interestingly, although there is no consensus, some studies show that cancer cells produce more EVs than normal cells \[[@B13-cells-09-01141],[@B35-cells-09-01141]\]. However, others report the lack of statistical difference in the levels of plasma EVs between cancer patients and healthy people \[[@B19-cells-09-01141],[@B36-cells-09-01141]\]. This conflicting evidence might be attributed to a low inter-laboratory reproducibility and to non-standardization of isolation and purification protocols for EVs \[[@B13-cells-09-01141]\].

Nevertheless, accumulating evidence suggests that tumor-derived EVs pay an important role in all steps of cancer progression, which makes them attractive for developing EV-based liquid biopsies for cancer patients ([Figure 1](#cells-09-01141-f001){ref-type="fig"}f). Compared to conventional biopsies they: (1) are a simpler and less invasive method for early diagnosis, (2) facilitate surveillance of the patient's cancer stage and treatment efficacy, and (3) offer surveillance of patient relapse and prognosis \[[@B29-cells-09-01141],[@B37-cells-09-01141],[@B38-cells-09-01141],[@B39-cells-09-01141]\]. However, some problems may have to be addressed when considering implementing EV-based liquid biopsies in the clinic, such as the time required for analysis, high costs involved, or need to find a compromise between high specificity and high sensitivity \[[@B39-cells-09-01141]\]. Additionally, the EVs retrieved from liquid biopsies are not necessarily representative of the most abundant cell type in a certain tissue \[[@B40-cells-09-01141]\]. Additionally, the EVs' populations, cargo levels, and selective packaging are highly heterogeneous and changeable under different physiological conditions, internal cellular processes or external stimuli (such as temperature and stress), thus offering a mere snapshot of the molecular circumstances in their cell of origin at their point of release from cells \[[@B2-cells-09-01141],[@B41-cells-09-01141],[@B42-cells-09-01141]\]. In addition, the isolation, purification, and characterization of EVs as well as the separation of EV subpopulations, still requires standardization. To this end, many novel methods are under development varying in cost, sensitivity, purity and time required \[[@B1-cells-09-01141],[@B2-cells-09-01141],[@B33-cells-09-01141],[@B43-cells-09-01141]\]. Selection of the purification method to be used should be based on the sample type and amount as well as the downstream analysis to be performed \[[@B1-cells-09-01141],[@B33-cells-09-01141]\]. Additionally, specific methods might bias the retrieval of certain subpopulations of EVs \[[@B43-cells-09-01141]\].

EVs are also being considered for cancer therapy, either as cancer vaccines or as drug delivery systems to accumulate certain drugs or siRNAs at specific tumor sites, while reducing toxicity-related adverse effects \[[@B44-cells-09-01141],[@B45-cells-09-01141],[@B46-cells-09-01141],[@B47-cells-09-01141]\].

The following section reviews recent findings on the association of cancer-derived EVs with the well-known cancer hallmarks and with cancer drug resistance.

2. Tumor-Derived EVs affecting Cancer Hallmarks {#sec2-cells-09-01141}
===============================================

As mentioned above, EVs released by some cells (the donor cells) can be taken up by other cells (the recipient cells) where they release their cargo, thus being responsible for intercellular communication \[[@B3-cells-09-01141]\]. Several studies have revealed the remarkable impact of tumor-derived EVs on the well-known cancer hallmarks, ultimately interfering with cancer progression and drug resistance. Indeed, the effect of tumor-derived EVs on sustained cellular proliferation and resistance to cell death, induction of angiogenesis, promotion of invasion and metastasis, reprogramming of cellular energy metabolism, evasion from immune response, transfer of mutations, and modulation of the TME underpins their relevance as central mediators in key cancer processes ([Figure 2](#cells-09-01141-f002){ref-type="fig"}).This will be reviewed in the following sections, together with the EVs cargo derived from different types of cancers and identified to have a biological relevance ([Table 1](#cells-09-01141-t001){ref-type="table"}).

2.1. Promoting Cell Proliferation and Escape from Apoptosis {#sec2dot1-cells-09-01141}
-----------------------------------------------------------

EVs released by cancer cells can support the enrolment of normal cells into the tumorigenic process, facilitating their phenotypical transformation and thus contributing to tumor growth by promoting proliferative signaling. Additionally, EVs can support cancer cells escape from apoptosis. For example, a study \[[@B48-cells-09-01141]\] showed that the splicing factor RBM11 present in EVs released by glioblastoma cell lines was transferred to recipient tumor cells and induced the splicing of MDM4 and Cyclin D1 into a more oncogenic isoform, contributing to an increase in survival and impairing apoptosis. In addition, in vivo work in mice injected with EVs from glioblastoma cells confirmed the potential of those EVs in promoting malignancy in recipient tumor cells \[[@B48-cells-09-01141]\]. Another study demonstrated that EVs released by glioblastoma cells (either cell lines or patient-derived cancer stem cells) mediated the intercellular transfer of the protein chloride intracellular channel-1 (CLIC1), supporting the growth of other (recipient) glioblastoma cells. In the same study, the injection of glioblastoma cells with EVs containing CLIC1 into nude mice enhanced tumor growth when compared with EVs not containing CLIC1 \[[@B49-cells-09-01141]\]. In melanoma, the transfer of PDGFR-β mediated by EVs released by melanoma (donor) cells caused an activation of the PI3K/Akt pathway and escape from the MAPK pathway on BRAF mutated (recipient) cells, contributing to cellular proliferation and inhibition of apoptosis \[[@B50-cells-09-01141]\]. In fact, the activation of the PI3K/AKT and MAP/ERK pathways mediated by EVs was also verified in other cancer cell types. For instance, EVs released by bladder and gastric cancer cells promoted cell proliferation and inhibited apoptosis of recipient cancer cells through the activation of both pathways \[[@B116-cells-09-01141],[@B117-cells-09-01141]\].

Other mechanisms contributing to the promotion of tumor cell proliferation mediated by EVs were also described such as the intercellular transfer between pancreatic cancer cells of the zinc transporter ZIP4, leading to enhancement of tumorigenesis. In vivo, EVs released by pancreatic cancer cells injected into a nude mouse model promoted a more rapid and larger tumor growth than EVs from those cells that had been knocked down for ZIP4 \[[@B51-cells-09-01141]\]. Moreover, colon cancer derived EVs containing high levels of N-terminal truncated isoforms of p73 (DNp73) mRNA stimulated the growth of recipient cells. This result was subsequently confirmed in vivo using mice injected with EVs from DNp73 overexpressing cells, giving rise to greater tumor size when compared to mice injected with EVs from control cells \[[@B56-cells-09-01141]\].

The relevance of microRNAs (miRNAs) present in the cargo of EVs on cancer cell proliferation and apoptosis has also been verified in several studies. For instance, EVs shed by esophageal cancer cells transfer miR-93-5p to recipient neighbour cancer cells, affecting PTEN expression and its downstream proteins, p21 and cyclin D1, thus increasing cell proliferation of recipient cells \[[@B52-cells-09-01141]\]. Other examples are those of miR-1246 (which suppresses clyclin-G2 (CCNG2) levels) on EVs shed by breast cancer cells \[[@B54-cells-09-01141]\] and miR-205 on EVs shed by cholangiocarcinoma cells \[[@B55-cells-09-01141]\], which impacted cancer cell proliferation. Moreover, EVs shed by colon cancer cells containing high levels of miR-193a and mir-200b were responsible for the promotion of colon cancer cellular proliferation. Further in vivo work proved the impact of miR-193a and miR200b on tumor progression, using tumor-bearing nude mice or tumor xenografts, respectively, injected with EVs containing the respective miRNAs \[[@B57-cells-09-01141],[@B58-cells-09-01141]\]. EVs released by pancreatic cancer cells in vitro transferred miR-23b-3p \[[@B53-cells-09-01141]\] and miR-222 \[[@B118-cells-09-01141]\] to neighboring cancer cells in order to promote cell proliferation. Interestingly, the miR-23b-3p was isolated from the plasmatic EVs of pancreatic cancer patients \[[@B53-cells-09-01141]\]. Remarkably, miR-222 and miR-146b were found to be overexpressed in EVs released by papillary thyroid cancer cells, being responsible for cancer cell proliferation in vitro \[[@B60-cells-09-01141]\]. The involvement of miRNAs from EVs released by gastric cancer cells on cancer cell proliferation via CD97-associated pathways, such as the MAPK signaling pathway, was also observed \[[@B119-cells-09-01141]\]. EVs containing miR-21 from ovarian serous carcinoma cells also contributed to malignant transformation and progression, through post-transcriptional inhibition of the tumor suppressor programmed cell death 4 (PDCD4) \[[@B61-cells-09-01141]\]. In leukemia, EVs isolated from patient samples had a specific miRNA signature when compared to EVs from healthy donors. This suggests that miRNAs carried by EVs are likely to be involved in the tumorigenesis of this cancer type \[[@B62-cells-09-01141]\].

Long non-coding RNAs (lncRNA) present on EVs released by cancer cells also have a role in cancer progression and apoptosis. Indeed, various lncRNAs found in the cargo of EVs released by many tumor cell lines favoured cancer cell growth, including the lncRNA ZFAS1 in EVs released by gastric cancer cells \[[@B63-cells-09-01141]\], lncRNA PVT1 in EVs released by colon cancer cells \[[@B59-cells-09-01141]\], lncRNA ZEB1-AS1 in EVs shed by esophageal cancer cells \[[@B64-cells-09-01141]\] and lncRNA TUC339 in EVs released by hepatocellular carcinoma cells \[[@B65-cells-09-01141]\]. Remarkably, the clinical impact of the lncRNA ZEB1-AS1 was observed by its detection at higher levels in EVs isolated from esophageal cancer patients when compared to EVs from healthy individuals \[[@B64-cells-09-01141]\].

2.2. Sustaining Angiogenesis {#sec2dot2-cells-09-01141}
----------------------------

The development of de novo vasculature is essential for tumor growth and metastasis and EVs are key players in this process. Indeed, the ability of tumor-derived EVs to sustain angiogenesis by promoting communication between cancer cells and endothelial cells has been described. Several studies report the effect of EVs released by glioma cells on angiogenesis. In these studies, the angiogenesis process was enhanced via upregulation of the vascular endothelial growth factor (VEGF) on recipient endothelial cells which was caused by the presence of promoting-angiogenic factors on the cargo of EVs, such as lncRNA CCAT2 \[[@B66-cells-09-01141]\], lncRNA POU3F3 \[[@B67-cells-09-01141]\], miR-21 \[[@B68-cells-09-01141]\] or CXCR4 receptor \[[@B69-cells-09-01141]\]. The VEGF has also been detected in the cargo of EVs and was found to contribute to angiogenesis stimulation \[[@B68-cells-09-01141],[@B69-cells-09-01141]\]. Moreover, EVs from head and neck squamous cell carcinoma also exerted an effect, both in vitro and in vivo, in driving tumor angiogenesis through the ephrin type B receptor 2 (EPHB2) \[[@B70-cells-09-01141]\]. Another study showed that EVs released by hepatocellular carcinoma cells promoted endothelial cell migration in vitro, through vasorin transfer which plays a role in vasculogenesis \[[@B71-cells-09-01141]\]. EVs shed by multiple myeloma cells carry a piwi-interacting RNA (the piRNA-823, that belongs to a class of small non-coding RNAs), which is able to re-educate endothelial cells towards an environment amenable to the growth of multiple myeloma cells, by enhancing VEGF, interleukin 6 (IL-6) and ICAM-1 (intercellular adhesion molecule 1) expression. In addition, EVs carrying piRNA-823 promoted the growth of xenograft tumors in vivo \[[@B73-cells-09-01141]\]. Furthermore, miR-25-3p secreted via EVs shed by colon cancer cells was delivered to vascular endothelial cells, disrupting the integrity of endothelial barriers, and thus inducing vascular permeability and angiogenesis. An induction of the pre-metastatic niche formation was also observed when EVs derived from colon cancer cells containing miR-25-3p were injected into nude mice \[[@B74-cells-09-01141]\]. Similarly, hepatocellular carcinoma cells secreted EVs containing miR-103 which attenuated the endothelial junction integrity by directly inhibiting the expression of VE-Cadherin, p20-catenin, and zonula occludens 1, thus increasing vascular permeability \[[@B72-cells-09-01141]\]. Moreover, in lung cancer, the intercellular transfer mediated by EVs of miR-14-3p and miR-145-5p from cancer cells to endothelial cells, led to an increase of tube formation by endothelial cells and thus promoted angiogenesis \[[@B75-cells-09-01141]\]. Also, EVs from epithelial ovarian cancer cells containing miRNA-141-3p promoted endothelial cell angiogenesis through activation of the JAK/STAT3 and NF-κB signaling pathways \[[@B77-cells-09-01141]\]. Another group also demonstrated in vitro that ovarian cancer cell-derived EVs induced the expression of VEGF in endothelial cells, thus influencing their vascular behaviour \[[@B120-cells-09-01141]\]. Moreover, EVs shed by oral cancer cells contained miR-142-3p that could be taken up by recipient endothelial cells, promoting angiogenesis mediated by the protein TGFBR1. Increased vascular density by miR-142-3p was confirmed in vivo using miR-142-3p overexpression in the mouse xenograft model of oral cancer \[[@B78-cells-09-01141]\]. Curiously, EVs released by lung cancer cells during radiation therapy had increased levels of miR-23a which promoted endothelial cell angiogenesis, suggesting that this could be a resistance mechanism to this type of therapy \[[@B76-cells-09-01141]\].

Of note however, are studies reporting contradictory effects of EVs on angiogenesis. For example, in nasopharyngeal carcinoma, EVs containing miR-23a induced angiogenesis by directly targeting the testis-specific gene antigen (TSGA10) \[[@B79-cells-09-01141]\] while EVs containing miR-9 were anti-angiogenic by regulating the PDK/Akt pathway \[[@B121-cells-09-01141]\]. The levels of miR-23a on EVs isolated from the serum of metastatic nasopharyngeal carcinoma patients were higher than on EVs derived from healthy volunteers \[[@B79-cells-09-01141]\]. Likewise, EVs shed by oral squamous carcinoma cells also presented pro- or anti-angiogenic properties, depending on the invasive capacity of the cells \[[@B122-cells-09-01141]\].

2.3. Contributing to Cancer Cell Invasion and Metastasis {#sec2dot3-cells-09-01141}
--------------------------------------------------------

Several studies have demonstrated the involvement of EVs in tumor metastasis through the stimulation of cancer cell migration and invasion. For example, some studies underline the role of EVs shed by prostate carcinoma cells in enhancing cell motility and metastatic potential of cancer cells and in inducing malignant features in normal prostate cells. The mechanisms proposed include the induction of mesenchymal traits in non-tumor cells \[[@B123-cells-09-01141]\], modulation of the androgen receptor and TGF-β signaling \[[@B124-cells-09-01141]\], or the alteration in cellular levels of tetraspanins CD9 and CD151 \[[@B125-cells-09-01141]\] in the recipient cancer cells.

The horizontal transfer mediated by EVs of molecules responsible for enhancing cellular migration and facilitating invasion of recipient cancer cells was also observed in other cancer cell types. These include in metastatic breast cancer cells through Caveolin-1 transfer \[[@B80-cells-09-01141]\], in colon cancer cells by Wnt5b protein transfer \[[@B81-cells-09-01141]\] and in hepatocarcinoma cell lines through the transfer of CXC chemokine receptor 4, CXCR4 \[[@B84-cells-09-01141]\] or SMAD3 \[[@B83-cells-09-01141],[@B85-cells-09-01141]\]. In fact, the clinical value of SMAD3 was confirmed by its presence at high levels in EVs isolated from hepatocellular carcinoma patients when compared to EVs isolated from patients with benign hepatomas or from healthy donors \[[@B85-cells-09-01141]\]. In renal carcinoma, EVs shed by cancer cells inhibited hepaCAM (a cell adhesion molecule) in a p-Akt dependent manner, thus promoting malignancy by increasing cell migration \[[@B126-cells-09-01141]\]. Interestingly, the status of KRAS was found to be essential for the ability of colon cancer cells to invade. EVs derived from malignant donor cells with the KRAS mutant allele have high amounts of amphiregulin (AREG), which is a ligand for EGFR, increasing the potential invasiveness and metastasis in recipient cells \[[@B82-cells-09-01141]\]. Moreover, colon cancer cell EVs were also shown to induce hepatocellular cancer cells migration via activation of the MAPK/ERK pathway in recipient cells \[[@B127-cells-09-01141]\].

The role of miRNAs from the cargo of EVs on recipient cancer cells invasion and migration has also been described in vitro. One example includes the identification of miR-205-5p or miR-423-5p in EVs released by cholangiocarcinoma or by gastric cancer cells respectively \[[@B55-cells-09-01141],[@B87-cells-09-01141]\]. In vivo studies also demonstrated that the injection of EVs enriched in miR-423-5p into xenografts increased the number of metastatic tumor nodes. At a clinical level, higher expression of miR-423-5p was detected in EVs isolated from the serum of gastric cancer patients than in EVs isolated from healthy volunteers \[[@B87-cells-09-01141]\]. Additionally, in EVs shed by hepatocellular carcinoma cancer cell lines, miR-93 \[[@B86-cells-09-01141]\] and miR-103 \[[@B72-cells-09-01141]\] were also found to contribute to cancer cell invasiveness. Furthermore, higher levels of miR-93 were observed in EVs isolated from hepatocellular carcinoma patients than from healthy controls, related with a large tumor size and later tumor stage \[[@B86-cells-09-01141]\]. Moreover, the presence of miR-103 in EVs derived from tumor-bearing mice was associated with increased vascular permeability and tumor metastasis \[[@B72-cells-09-01141]\]. In another study, EVs shed by prostate carcinoma cell lines contained miR-1246 that inhibits N-cadherin and vimentin activities, which then inhibited epithelial-mesenchymal transition (EMT). The miR-1246 was detected in EVs isolated from the serum of xenograft mouse models and from the serum of aggressive prostate cancer patients \[[@B88-cells-09-01141]\]. Other work reported that EVs isolated from the serum of glioblastoma patients encapsulated increased levels of miR-148a. This targeted the cell adhesion molecule 1 (CADM1) when compared to EVs isolated from healthy volunteers, suggesting that miR-148a might be involved in cancer invasion \[[@B89-cells-09-01141]\]. The presence of miR-99a-5p in EVs released by ovarian cancer cell lines increased fibronectin and vitronectin expression in peritoneal mesothelial cells, promoting cancer cell invasion \[[@B90-cells-09-01141]\].

2.4. Reprogramming Energy Metabolism {#sec2dot4-cells-09-01141}
------------------------------------

Tumor cells can reprogram their energy metabolism to fuel their rapid cell growth and proliferation. The role of tumor-derived EVs on this mechanism has also been shown. For example, our group demonstrated that EVs derived from leukaemia or lung cancer multidrug resistant cells induced a metabolic switch in recipient drug-sensitive cancer cells, by causing a decrease in the pentose phosphate pathway and an increase in glycolysis \[[@B128-cells-09-01141]\]. Other authors found that EVs from adriamycin-resistant breast cancer cells contained high amounts of glutathione S-transferase P1 (GSTP1, a phase II metabolic enzyme capable of detoxifying damaging chemicals from cells), which was transferred to sensitive cells. This study also showed that EVs isolated from the serum of breast cancer patients who did not respond to chemotherapy had higher GSTP1 levels than EVs from patients who responded to the treatment \[[@B91-cells-09-01141]\]. Interestingly, EVs secreted by breast cancer cells reprogrammed glucose metabolism in recipient non-tumor cells through the transfer of miR-122, which facilitated disease progression. Moreover, orthotopic mammary xenografts injected with EVs containing high levels of miR-122 presented reduced uptake of glucose into the brain and lungs, giving rise to a reduced expression of pyruvate kinase and glucose transporter 1, GLUT1 \[[@B92-cells-09-01141]\].

2.5. Transferring Mutations {#sec2dot5-cells-09-01141}
---------------------------

Evidence suggests that tumor-derived EVs contain pieces of DNA that might comprise the entire genome. It is still not understood how DNA is packaged inside EVs and if DNA transferred by EVs is functional in recipient cells \[[@B129-cells-09-01141]\]. However, recent literature suggests some functional role for DNA transferred by EVs. Indeed, the fusion genes PTPRZ1-Met can be present on the cargo of EVs released by glioblastoma cell lines and transferred to other glioblastoma cells, causing a more aggressive phenotype in the recipient cells. In vivo, xenografts injected with EVs carrying PTPRZ1-Met harbour larger tumors, confirming the role of those EVs containing PTPRZ1-Met in tumorigenesis \[[@B93-cells-09-01141]\]. The truncated and functional forms of Alk (Anaplastic Lymphoma Kinase) mRNAs were also found in the cargo of EVs released by melanoma drug resistant cells, being transferred to sensitive cells and activating the MAPK signaling pathway in the recipient cells \[[@B95-cells-09-01141]\]. Similarly, aggressive glioma cells expressing EGFRvIII, a truncated oncogenic form of the epidermal growth factor receptor (EGFR), released EVs containing EGFRvIII which were taken up by recipient glioma cells lacking this isoform, thus promoting the activation of the MAPK and Akt signaling pathways \[[@B94-cells-09-01141]\]. EVs derived from colorectal cancer cells contained the oncogenic mutant β-catenin which activated WNT signaling in recipient cells with wild-type β-catenin, promoting cancer progression \[[@B96-cells-09-01141]\]. In addition, EVs released by epithelial ovarian cancer cell lines carrying SMAD4 mutations enhanced platinum-resistant phenotype in recipient drug-sensitive ovarian cancer cells, suggesting a possible transfer of SMAD4 mutations through EVs \[[@B97-cells-09-01141]\].

2.6. Modulating the TME: Evading Immune Response and Promoting Inflammation {#sec2dot6-cells-09-01141}
---------------------------------------------------------------------------

Most tumor cells express antigens that can mediate recognition by the immune system. However, some cancer cells are able to evade the antitumor immune response and continue proliferating. Also, tumor progression is closely related to chronic inflammatory processes and may involve deregulation in activity of various types of immune cells. Remarkably, several studies have extensively described the role of EVs released by tumor cells on different types of neighbouring cells present in the surrounding TME and which are involved in inflammation or immune response.

Most of the studies revealed the impact of EVs on TME modulation towards a tumor promoting and supporting environment. Nevertheless, we should be aware that some reports have shown contradicting data, with EVs inducing an anticancer immune response. For example, EVs derived from heat-stressed tumor cells converted immunosuppressive regulatory T cells into T helper cells, which contributed to their potent antitumor effect \[[@B130-cells-09-01141]\]. Also, EVs from leukemia cells injected into a mouse tumor model prevented tumor formation \[[@B131-cells-09-01141]\].

### 2.6.1. Impact of Tumor-Derived EVs on Macrophages {#sec2dot6dot1-cells-09-01141}

Many studies show that EVs released by tumor cells can transfer their cargo to macrophages. For example, EVs released by ovarian cancer cells transferred the oncogenic miR-1246 to M2-type tumor-associated macrophages but not to M0-type naïve macrophages, suggesting that EVs from cancer cells interfere with the TME, which then plays a role in tumor progression \[[@B98-cells-09-01141]\]. Indeed, miR-1246 was also detected on EVs released by colon cancer cells and could reprogram macrophages to induce the production of tumor supportive factors, such as IL-10 and metalloproteinases (MMPs) \[[@B100-cells-09-01141]\]. Furthermore, Casadei et al. demonstrated in vitro that miR-25-3p and miR-921-3p present in EVs secreted by liposarcoma cell lines were capable of stimulating the secretion of the pro-inflammatory cytokine IL-6 from macrophages, which in turn stimulated cancer cell proliferation. In addition, the presence of those miRNAs in EVs isolated from the plasma of liposarcoma patients was confirmed \[[@B103-cells-09-01141]\]. Another study reported that EVs isolated from glioblastoma cells containing high levels of miRNAs (such as miR-21) were taken up by macrophages in a glioma-bearing brain mouse model, confirming the influence of EVs released by glioblastoma cells in the TME \[[@B104-cells-09-01141]\]. Also, EVs released by hepatocellular carcinoma cell lines contain the lncRNA TUC339 which can regulate macrophage activation and induce an M2 macrophage polarization, favoring cancer cell progression \[[@B106-cells-09-01141]\]. Interestingly, EVs released by ovarian cancer cell lines under hypoxia conditions contained high levels of miR-940, inducing macrophage M2 polarization \[[@B132-cells-09-01141]\]. However, contradictory data showed that EVs shed by melanoma cell lines activated macrophages, and also helped the maturation of dendritic cells and enhanced T-cell proliferation. Nonetheless, this study showed mixed biological effects, with the role of EVs not only in promoting antitumor immune response, but also in tumor immune escape \[[@B133-cells-09-01141]\].

### 2.6.2. Impact of Tumor-Derived EVs on T Lymphocytes {#sec2dot6dot2-cells-09-01141}

The T lymphocytes may also be modulated by tumor-derived EVs. For example, some EVs derived from glioblastoma cells expressed the transmembrane protein PD-L1, which has the potential to bind PD1 and block T-cell activation and proliferation \[[@B105-cells-09-01141]\]. Furthermore, EVs shed by nasopharyngeal carcinoma cell lines promoted T-cell dysfunction, which was mediated by miR-24-3p through repression of targeting fibroblast growth factor (FGF)11 \[[@B108-cells-09-01141]\]. Moreover, the miR-24-3p was markedly enriched in EVs derived from nasopharyngeal carcinoma patients' serum when compared to healthy donors and correlated with worse disease-free survival of patients \[[@B109-cells-09-01141]\]. Other studies have also demonstrated that colon cancer cell lines released EVs containing members of the carcinoembryonic antigen related cell adhesion molecule (CEACAM)-family. These influenced T-cell behavior \[[@B101-cells-09-01141]\] or induced phenotypic alterations on T-cells via activation of the TGF-β/Smad signaling \[[@B134-cells-09-01141]\], supporting tumor cell growth. In addition, EVs released by breast cancer cells suppressed T-cells by delivering TGF-β directly to these immune cells \[[@B135-cells-09-01141]\]. EVs shed by kidney adenocarcinoma cells triggered T-cell apoptosis through the transfer of the Fas ligand \[[@B111-cells-09-01141]\]. Similarly, other cancer types such as melanoma, prostate, oral and colorectal were shown to release EVs containing the Fas ligand which were taken up by T-cells \[[@B136-cells-09-01141],[@B137-cells-09-01141],[@B138-cells-09-01141],[@B139-cells-09-01141]\], again demonstrating the significant role of EVs in eliminating the most effective cells with antitumor response. Interestingly, like the Fas ligand, galectin-9 also mediates apoptosis when bound to its receptor. EVs derived from nasopharyngeal carcinoma cells (which contained galectin-9) were taken up by mature T cells. The interaction between galectin-9 and the Tim-3 receptor from T cells triggered T cells apoptosis \[[@B110-cells-09-01141]\]. Moreover, EVs released by nasopharyngeal carcinoma cells liberated miRNAs which through inhibition of the MAP-kinase pathway, originated a decrease in T-cell proliferation \[[@B109-cells-09-01141]\]. Furthermore, EVs derived from ovarian carcinoma cells contained the metabolic checkpoint molecule arginase-1, which suppressed T-cell responses and promoted tumor growth \[[@B99-cells-09-01141]\]. Curiously, although to a large extent unexplored, the modulation of B-lymphocytes by EVs has also been reported. EVs shed by esophageal cancer cell lines induced naïve B cells differentiation into TGF-β-producing regulatory B cells, contributing to immune suppressor functions on T-cell proliferation \[[@B140-cells-09-01141]\].

### 2.6.3. Impact of Tumor-Derived EVs on Fibroblasts {#sec2dot6dot3-cells-09-01141}

EVs-mediated communication between tumor cells and fibroblasts has been reported. An in vitro study showed that EVs shed by chronic lymphocytic leukemia cells were actively incorporated by surrounding stromal cells, inducing features of cancer-associated fibroblasts (CAFs), resulting in the secretion of inflammatory cytokines that contributed to a tumor-supportive microenvironment. This effect was also observed in vivo, by injecting labeled EVs into mice and following the targeted cells \[[@B141-cells-09-01141]\]. In addition, EVs released by ovarian cancer cell lines \[[@B142-cells-09-01141]\] or by Hodgkin lymphoma cells \[[@B143-cells-09-01141]\] modulated normal fibroblasts behavior, altering their phenotype (activating them to a CAFs-like state) to support tumor growth and progression. Interestingly, EVs released by gastric cancer cell lines enhanced pericytes proliferation and migration, and induced the expression of CAFs markers in pericytes \[[@B144-cells-09-01141]\].

The function of miRNAs delivered via EVs as messengers between tumor cells and fibroblasts at the TME has also been described. For example, the miR-21 present in EVs from hepatocellular carcinoma cell lines aided tumor progression by converting normal hepatocytes stellate cells to CAFs. Clinical data also indicated that high levels of EVs containing miR-21, isolated from the serum of hepatocellular carcinoma patients, were correlated with a greater activation of CAFs and higher vessel density \[[@B107-cells-09-01141]\]. Interestingly, the miR-675 present in EVs released by metastatic osteosarcoma cell lines down-regulated CALN1 expression on non-malignant fibroblast cells, increasing their migration and invasion capacities \[[@B112-cells-09-01141]\]. Similarly, primary pancreatic fibroblasts isolated from mice were converted into CAFs-like cells in the presence of EVs released by pancreatic cancer cell lines, in a process mediated by miR-155 contained in the EVs cargo \[[@B145-cells-09-01141]\]. Moreover, miRNAs present in EVs released by several tumor cells induced in vitro the reprogramming of fibroblasts into CAFs, to support tumor growth. This was shown in EVs derived from gastric cancer, colorectal cancer, melanoma and lung cancer cells and was mediated by the transfer of miR-27a \[[@B113-cells-09-01141]\], miR-10b \[[@B102-cells-09-01141]\], miR-155-5p \[[@B114-cells-09-01141]\] and miR142-3p \[[@B115-cells-09-01141]\], respectively.

3. Tumor-Derived EVs Affecting Cancer Therapy Resistance {#sec3-cells-09-01141}
========================================================

Extracellular vesicles may promote resistance to chemotherapy and targeted therapy in cancer, including multidrug resistance (MDR). This is due to the intercellular transfer of drug resistant traits between cancer cells or between cancer cells and the tumor microenvironment, as explained in the following sections ([Figure 3](#cells-09-01141-f003){ref-type="fig"}).

3.1. Intercellular Transfer of Drug Resistant Traits between Cancer Cells {#sec3dot1-cells-09-01141}
-------------------------------------------------------------------------

The mediators of the intercellular transfer of drug resistant traits between resistant and sensitive cancer cells will be discussed in the following sections ([Table 2](#cells-09-01141-t002){ref-type="table"}).

### 3.1.1. Transferring Drug-Efflux Pumps {#sec3dot1dot1-cells-09-01141}

EVs shed by drug resistant cancer cells may transfer drug efflux pumps to sensitive recipient cancer cells, causing drug efflux in the recipient cells, thereby reducing drug concentrations to sublethal levels \[[@B3-cells-09-01141],[@B196-cells-09-01141],[@B197-cells-09-01141]\]. Amongst the drug efflux pumps, various members of the ATP-binding cassette (ABC) family, namely breast cancer resistance protein (BRCP/ABCG2), ABCA3, multidrug resistance-associated protein 1 (MRP1/ABCC1), and P-glycoprotein (P-gp/MDR1/ABCB1) \[[@B146-cells-09-01141],[@B147-cells-09-01141],[@B157-cells-09-01141],[@B198-cells-09-01141],[@B199-cells-09-01141]\] have been shown to be transferred by EVs from drug-resistant cells to drug-sensitive cells. The orientation of these transporters may be inverted in some EVs when compared to their orientation in their donor cells, thus possibly promoting drug-influx rather than efflux into EVs \[[@B197-cells-09-01141]\].

The non-genetic acquisition of P-gp mediating drug resistance or enrichment on this drug efflux pump in EVs shed by drug-resistant cells has been reported in many studies. These include castration-resistant prostate cancer cells after docetaxel exposure \[[@B148-cells-09-01141],[@B149-cells-09-01141]\], breast cancer cells following docetaxel \[[@B150-cells-09-01141]\], adriamycin \[[@B151-cells-09-01141],[@B152-cells-09-01141],[@B153-cells-09-01141]\], or doxorubicin \[[@B154-cells-09-01141]\] exposure in paclitaxel-resistant ovarian cancer cells \[[@B156-cells-09-01141]\], doxorubicin-resistant osteosarcoma cells \[[@B155-cells-09-01141]\], in multidrug-resistant leukemia \[[@B146-cells-09-01141],[@B157-cells-09-01141]\], and in neuroblastoma cells \[[@B158-cells-09-01141]\]. Intercellular transfer of functional P-gp has also been reported in vivo in a neuroblastoma xenograft mouse model \[[@B158-cells-09-01141]\] and breast cancer xenograft model \[[@B200-cells-09-01141]\].

It is unclear whether the intercellular transfer of the EVs cargo is a selective or a random process. The transfer of P-gp through EVs released by drug-resistant leukemia cells displayed no cell-type selectivity between breast and lung cancer recipient cells \[[@B163-cells-09-01141]\]. Additionally, this cargo was reported to be transferred (along with MRP1) to both malignant and non-malignant recipient cells whereas EVs from breast cancer cells only transferred P-gp to malignant cells \[[@B200-cells-09-01141]\].

It was recently reported the EV-mediated intercellular transfer of ABCB1 protein from drug-resistant KBv200 cells to drug-sensitive KB cells constituted one mechanism behind the acquisition of a resistant phenotype, following exposure to either vincristine, cisplatin or doxorubicin \[[@B159-cells-09-01141]\]. Interestingly, as the tested chemotherapeutic agents possess distinct chemical structures and mechanisms of action, the authors concluded that independently of being an ABCB1 substrate, conventional chemotherapeutic drugs can still promote the transfer of this protein through EVs \[[@B159-cells-09-01141]\]. Another study reported that MRP1-containing EVs were responsible for the transfer of a multidrug resistance phenotype from resistant HL-60 cells to recipient cells, and highlighted the differential expression of miR-19b and miR-20a between EVs from chemo-resistant and chemo-sensitive cells \[[@B146-cells-09-01141]\].

Moreover, human acute lymphoblastic leukemia cells (CCRF--CEM) exposed to EVs from their multidrug-resistant subline (VLB~100~) displayed increased expression of P-gp. This could not be explained by the transcription and posterior translation of the MDR1 gene (due to the short incubation time of two and four hours), suggesting that there was a direct intercellular transfer of this drug efflux pump \[[@B157-cells-09-01141]\].

Moreover, a prolonged expression of P-gp that extended well beyond the half-life of this protein was reported after a single exposure of a breast tumor (MCF7) xenograft model to EVs retrieved from drug-resistant cells \[[@B200-cells-09-01141]\]. This demonstrates the EVs' capacity to disseminate a stable resistant phenotype and suggests the concomitant action of the transferred P-gp with other transferred cargo such as miRNAs, mRNAs or possibly DNA fragments \[[@B3-cells-09-01141],[@B14-cells-09-01141]\]. Indeed, it has been demonstrated that the knock-down of the MDR1 gene in donor cells does not impede the transfer of resistance, suggesting that other mechanisms are involved in this process \[[@B201-cells-09-01141]\].

Adriamycin-resistant MCF7 cells transfer TrpC5 protein through EVs to recipient cells, activating the transcription factor NFATc3 which in turn leads to MDR1 gene expression, culminating in P-gp production in recipient cells \[[@B152-cells-09-01141]\]. Of interest is a study with breast cancer patients reporting TrpC5-containing EVs in only those who received chemotherapy \[[@B202-cells-09-01141]\].

### 3.1.2. Transferring Apoptotic Modulators {#sec3dot1dot2-cells-09-01141}

Other studies report EV-mediated drug resistance through the targeting of apoptosis regulators, promoting the induction of anti-apoptotic pathways in recipient cells such as the Bcl-2/BAX signaling \[[@B185-cells-09-01141]\]. Kreger et al. reported that an enrichment in the anti-apoptotic protein survivin in EVs retrieved from MDA-MB-231 triple-negative breast cancer cells previously treated with paclitaxel, induced resistance to this chemotherapeutic drug and promoted survival of serum-starved or paclitaxel-treated fibroblasts and SKBR3 breast cancer cells, when co-incubated with the same EVs \[[@B162-cells-09-01141]\]. Moreover, EVs from drug-resistant chronic myeloid leukemia cells gave rise to an accumulation in recipient cells not only of P-gp and microRNAs (miR-27a, miR-451 and miR-21) related to P-gp expression, but also of the inhibitors of apoptosis proteins XIAP, IAP and survivin. These EVs induced drug resistance in drug-sensitive recipient breast and lung tumor cells, thus suggesting multifactorial mechanisms for drug resistance and apoptosis evasion \[[@B163-cells-09-01141]\].

### 3.1.3. Transferring Other Proteins {#sec3dot1dot3-cells-09-01141}

A recently published paper on proteasome variations of EVs retrieved from two cisplatin-resistant and one sensitive oral squamous cell carcinoma cell lines, reported 77 differentially expressed proteins in EVs from both resistant cell lines, predominantly downregulated and involved in EGFR-associated networks \[[@B164-cells-09-01141]\]. Interestingly, six of these proteins were involved in the regulation of metal ion transportation, (e.g., ATP1A1 and ATP1B3) and since cisplatin is a metal-based compound, their down-regulation may have halted the uptake of this drug by the resistant cells \[[@B164-cells-09-01141]\]. Of the four found upregulated proteins, TGM2 had previously been reported to play a role in EV selective packaging of cargo and in mediating chemoresistance in lymphoma and breast cancer \[[@B164-cells-09-01141],[@B203-cells-09-01141],[@B204-cells-09-01141]\]. Moreover, a recent proteomic study reported the enrichment of GSTP1 and p-STAT3 in EVs from 5-fluorouracil-resistant colorectal cancer cells and the role of p-STAT3 in the transfer of resistance was further confirmed in vivo \[[@B165-cells-09-01141]\]. Furthermore, Zhao et al. recently postulated that the EV-mediated transfer of CLIC1 protein induced vincristine resistance in gastric cancer cells in vitro, an effect suggested to be related to the up-regulation of P-gp and Bcl-2 \[[@B166-cells-09-01141]\].

### 3.1.4. Transferring microRNAs, mRNAs and lncRNAs {#sec3dot1dot4-cells-09-01141}

Other molecules in the EV cargo which may be involved in the intercellular transfer of drug resistance include microRNAs, functional mRNAs and lncRNAs as well as regulators of these molecules and the above-mentioned molecules (in [Section 3.1.1](#sec3dot1dot1-cells-09-01141){ref-type="sec"}, [Section 3.1.2](#sec3dot1dot2-cells-09-01141){ref-type="sec"}, [Section 3.1.3](#sec3dot1dot3-cells-09-01141){ref-type="sec"}) \[[@B3-cells-09-01141],[@B186-cells-09-01141],[@B187-cells-09-01141],[@B205-cells-09-01141],[@B206-cells-09-01141]\]. Some studies suggest that, in addition to the direct transfer through EVs of known inducers of multidrug resistance, an EV-mediated increase in the expression of these inducers in recipient cells may also occur.

#### miRNAs

Some studies have attempted to associate specific EV-transferred microRNAs to drug resistance. EVs isolated and purified from a multidrug-resistant chronic myeloid leukemia cell line induced drug resistance in MCF7 cells after co-culture, through the EV-mediated transfer of miR-21 which possibly led to the activation of the Akt signaling, thus regulating the NF-κB pathway \[[@B163-cells-09-01141]\]. Moreover, in lung cancer cells, cisplatin-resistance was mediated by EV's miR-96 which inhibited LIM-domain only protein 7 expression \[[@B168-cells-09-01141]\] whereas in breast cancer the miR-222 from EVs contributed to adriamycin-resistance \[[@B169-cells-09-01141]\]. Indeed, EVs from triple-negative breast cancer cells induced significantly higher docetaxel and doxorubicin resistance on non-tumor breast cells and led to differential expression of 138 genes and 70 miRNAs, where downstream genes of the MAPK pathway, such as R-RAS and MAPK3, as well as miR-155-5p, miR-542-3p, let-7, and miR-28, might have played important roles as mediators \[[@B170-cells-09-01141]\]. Another study compared the microRNA content of EVs isolated from three drug-resistant ovarian cancer cell lines (taxol-resistant SKOV3, cisplatin-resistant A2780 and multidrug-resistant HEYA8) versus their drug-sensitive counterparts and detected the presence of miR-183-5p in all three resistant cell lines. This study also suggested that miR-183-5p possibly induced drug-resistance by modulating MECP2, thus regulating cell proliferation and influencing the biological process of response to hypoxia \[[@B171-cells-09-01141]\]. Moreover, in pancreatic cancer, EVs' miR-155 mediated gemcitabine-resistance through the targeting of the pro-apoptotic p53 target gene TP53INP1 \[[@B172-cells-09-01141]\], repression of the gemcitabine-metabolizing gene DCK and promotion of ROS detoxification by transferring SOD2 and CAT transcripts \[[@B173-cells-09-01141]\]. In addition, the intercellular transfer of miR221/222 mediated by EVs promoted tamoxifen-resistance in ER-positive breast cancer MCF7 cells, through p27 and estrogen receptor α downregulation \[[@B174-cells-09-01141]\]. Another study showed that exosomal miR-19b promoted oxaliplatin-resistance in SW480 colorectal cancer cells and that the inhibition of this microRNA led to increased drug sensitivity \[[@B175-cells-09-01141]\]. Interestingly, the secretion of EVs containing tumor-suppressor miR-145 and miR-34a correlated positively with 5-fluorouracil resistance in human colon cancer DLD-1 cells \[[@B176-cells-09-01141]\]. Furthermore, EVs from sorafenib-resistant renal cell carcinoma cell lines promoted resistance to this drug in vitro and in vivo, through the transfer of miR-31-5p which directly promoted down-regulation of MLH1 expression, one of the seven proteins that constitute the mismatch repair system \[[@B177-cells-09-01141]\]. Additionally, elevated levels of miR-31-5p were found in circulating EVs from renal cell carcinoma patients with progressive disease during sorafenib therapy when compared to pre-therapy levels \[[@B177-cells-09-01141]\]. Other work demonstrated (by using microarray technology in four different lines of synovial sarcoma) that EV-encapsulated microRNA-761 enhanced pazopanib resistance, possibly through the downregulation of TRIP6, LMNA and SIRT3 expression \[[@B178-cells-09-01141]\]. Yin et al. also suggested that the EV-encapsulated miR-1238 plays a role in mediating temozolomide-resistance in glioblastoma cells in vitro and in vivo, by acting on CAV1 and activating the EGFR-PI3K-AKT-mTOR pathway \[[@B179-cells-09-01141]\]. Furthermore, a recent study using high throughput technology has reported the upregulation of two pseudogenes (a novel pseudogene and RNA 5.8S ribosomal pseudogene 2) in EVs released by both non-small cell lung cancer (NSCLC) and chronic myeloid leukemia MDR tumor models. The same study also observed increased levels of a miRNA panel (miR-204-5p, miR-139-5p, miR-29c-5p, miR-551b-3p, miR-29b-2-5p, and miR-204-3p) in the lung cancer model, when compared to their drug-sensitive counterparts \[[@B207-cells-09-01141]\]. Moreover, in NSCLC, cisplatin-resistance was induced by the transfer of miR-425-3p by EVs shed by resistant cells, which facilitated autophagic activation by targeting AKT1 in recipient cells \[[@B180-cells-09-01141],[@B181-cells-09-01141]\]. Another recent study reported that miR-744 (downregulated in EVs retrieved from sorafenib-resistant hepatocellular carcinoma cells and patient serum) can inhibit proliferation and sorafenib chemoresistance in HepG2 cells by targeting PAX2, thus being suggested as a molecular target for the development of a possible innovative treatment strategy \[[@B182-cells-09-01141]\]. Similarly, the downregulation of miR-100-5p in EVs retrieved from cisplatin-resistance lung cancer cells was capable of inducing resistance in recipient cells, an effect further confirmed in vivo \[[@B183-cells-09-01141]\]. Work using multidrug resistant leukemia cells showed that EVs transferred ABCB1 transcript to recipient cells, which suppressed the transporter ABCC1 through miR-326 \[[@B199-cells-09-01141]\].

#### mRNAs

Some mRNAs are responsible for the intercellular transfer of drug resistance. Using an ovarian cancer xenograft mouse model, DNA methyltranferase 1 (DNMT1) mRNA was shown to play an important role in EV-mediated cisplatin-resistance \[[@B184-cells-09-01141]\]. Moreover, the transfer of EVs from adriamycin-resistant breast cancer cells (which had increased levels in GSTP1 mRNA - coding for a drug-detoxifying enzyme) increased GSTP1 expression and induced resistance in recipient cells in an EV concentration-dependent manner \[[@B91-cells-09-01141]\].

#### lncRNAs

The lncRNAs linc-ROR \[[@B186-cells-09-01141]\] and linc-VLDLR \[[@B187-cells-09-01141]\], transferred by EVs, induced sorafenib and doxorubicin-resistance in hepatocellular carcinoma HepG2 cells, through induction of TGFβ and increased expression of ABCG2, respectively. The EVs-Linc-VLDLR-ABCG2 pathway also plays a role in promoting multidrug resistance in esophageal cancer cells \[[@B188-cells-09-01141]\]. Additionally, EV-mediated intercellular transfer of lncARSR (which promoted Sunitinib resistance through competitive binding with miR-34/miR-449) increased AXL and c-MET expression in renal cell carcinoma cells. Also, the levels of lncARSR found in the plasma and tumor tissues correlated with Sunitinib response in renal cell carcinoma patients \[[@B189-cells-09-01141]\]. Interestingly, the transfer of lncRNA HOTTIP through EVs promoted cisplatin resistance in gastric cancer cells by activating the HMGA I/miR-218 Axis. Moreover, high levels of EVs' lncRNA HOTTIP in patient serum also correlated with poor response to cisplatin treatment \[[@B190-cells-09-01141]\]. Of interest is that the EV-shuttled lncRNA HNF1A-AS1 acted as a competing endogenous RNA of miR-34b, upregulating TUFT1 and inducing cisplatin-resistance in cervical cancer cells \[[@B191-cells-09-01141]\]. Moreover, the spread of temozolomide-resistance by EVs from glioblastoma cells containing lncRNA SBF2-AS1 was confirmed both in vitro and in vivo, and its effect was suggested to be mediated by competition with miR-151a-3p to disinhibit XRCC4, a protein responsible for double-strand repair \[[@B192-cells-09-01141]\]. Finally, the lncRNA AGAP2-AS1 packaged into EVs, was found to promote trastuzumab resistance in two HER-2 positive breast cancer cell lines \[[@B193-cells-09-01141]\].

### 3.1.5. Transferring Lipids {#sec3dot1dot5-cells-09-01141}

Lipids have been shown to participate in EV-mediated drug resistance. For example, ceramide, which plays a role in EV biogenesis and cargo loading, also mediates drug resistance possibly through P-gp \[[@B208-cells-09-01141],[@B209-cells-09-01141],[@B210-cells-09-01141]\]. Additionally, a lipidomic study revealed variations in the expression of 35 phospholipids between EVs retrieved from a gefitinib-resistant lung cancer cell line and its sensitive parental cell line \[[@B194-cells-09-01141]\]. Moreover, acid sphingomyelinase expression in EVs from multiple myeloma cell lines increased following exposure to melphalan and bortezomib, leading to the transfer of a drug-resistant phenotype to chemosensitive cells. In addition, acid sphingomyelinase inhibition by amitriptyline resulted in increased drug sensitivity in recipient multiple myeloma cells and in primary multiple myeloma cells \[[@B195-cells-09-01141]\].

3.2. Intercellular Transfer of Traits between the Microenvironment and Tumor Cells {#sec3dot2-cells-09-01141}
----------------------------------------------------------------------------------

The bidirectional crosstalk between the TME and tumor cells also plays a fundamental part in EV-mediated drug resistance. Within stromal cells, EVs from CAFs induced: (i) resistance to 5-fluorouracil and oxaliplatin in colorectal cancer stem cells either retrieved from patient-derived mice xenografts or by sorting for CD133+ in colorectal cancer cells lines \[[@B211-cells-09-01141]\]; (ii) chemoresistance in colorectal cancer cells in vitro and in vivo through transfer of exosomal lncRNA H19 that activates the β-catenin pathway \[[@B212-cells-09-01141]\]; (iii) resistance to gemcitabine in pancreatic adenocarcinoma cells via the transfer of both mRNA encoding the resistance factor Snail and its target miR-146a \[[@B213-cells-09-01141]\]; (iv) oxaliplatin resistance in colorectal cancer cells through the transfer of the colorectal cancer-associated lncRNA (CCAL) and activation of the β-catenin pathway both in vitro and in vivo \[[@B214-cells-09-01141]\]; (v) cisplatin-resistance in head and neck cancer cells through the transfer of miR-196a, which targets CDKN1B and ING5 \[[@B215-cells-09-01141]\], and (vi) alongside cancer associated adipocytes, also lead to ovarian cancer cell resistance to paclitaxel through the transfer of miR-21, which binds to the APAF1 coding sequence and downregulates APAF1 expression \[[@B216-cells-09-01141]\].

Stromal cells EVs induced resistance in acute lymphoblastic leukemia cells through the transfer of galectin-3, leading to the NF-kB pathway activation \[[@B217-cells-09-01141]\]. These EVs also induced resistance to bortezomib in multiple myeloma cells, possibly through the activation of JNK, p38, p53, and Akt \[[@B218-cells-09-01141]\], and in breast cancer by stimulating NOTCH3 and the pattern recognition receptor RIG-I, which in turn activates a STAT1-dependent antiviral signaling \[[@B219-cells-09-01141]\].

Mesenchymal stem cells caused drug resistance in recipient breast cancer cells by releasing EVs with miR-222/miR-223 \[[@B220-cells-09-01141]\]. Additionally, ZEB1 mRNA, encapsulated into EVs from a mesenchymal NSCLC line, transferred gemcitabine and cisplatin resistance to a surrounding epithelial NSCLC line \[[@B221-cells-09-01141]\].

Fascinatingly, miR-21 containing EVs from neuroblastoma cells induced the release of monocyte EVs containing miR-155 which in turn induced cisplatin resistance on neuroblastoma cells, by entering these cells and repressing TERF1, both in vitro and in vivo \[[@B222-cells-09-01141]\].

3.3. Drug Efflux Mediated by EVs {#sec3dot3-cells-09-01141}
--------------------------------

Drug efflux from cancer cells is made possible through the secretion of drugs into the cargo of EVs shed by those cells \[[@B3-cells-09-01141],[@B197-cells-09-01141],[@B223-cells-09-01141]\]. Indeed, it has been suggested that: (a) cancer cells secreting more EVs achieve the greatest levels of resistance \[[@B149-cells-09-01141],[@B164-cells-09-01141],[@B223-cells-09-01141],[@B224-cells-09-01141],[@B225-cells-09-01141],[@B226-cells-09-01141]\] and that (b) drug-resistant cells can export larger quantities of drugs into their EVs than drug-sensitive cells \[[@B164-cells-09-01141],[@B167-cells-09-01141],[@B197-cells-09-01141],[@B225-cells-09-01141]\]. Interestingly, a massive increase in the release of EVs has been reported to be one of the responses of cancer cells to photodynamic treatment and chemotherapeutic drugs, both in vitro and in vivo \[[@B227-cells-09-01141]\].

3.4. Increased Release of EVs by Drug Resistant Cells {#sec3dot4-cells-09-01141}
-----------------------------------------------------

Some studies suggest that drug resistant cells produce more EVs than drug sensitive cells \[[@B147-cells-09-01141],[@B149-cells-09-01141],[@B197-cells-09-01141],[@B228-cells-09-01141],[@B229-cells-09-01141],[@B230-cells-09-01141]\]. Additionally, many studies report a direct association between the presence of some mediators of drug resistance and molecules involved in EV production, supporting the findings that drug resistant cells release more EVs than sensitive cells. For example, Annexin A3 that is involved in ovarian cancer cellular resistance to platinum \[[@B230-cells-09-01141],[@B231-cells-09-01141]\] and is detected in EVs from the same type of cancer resistant to cisplatin, also appears to be responsible for an increased production of EVs in the same cells \[[@B230-cells-09-01141]\]. Moreover, ABCG2 present in EVs has not only been reported to mediate resistance to mitoxantrone \[[@B160-cells-09-01141]\], topotecan, imidazoacridinones and methotrexate \[[@B161-cells-09-01141]\] in breast cancer cell lines, but has also been found to exert a role in EV production \[[@B229-cells-09-01141]\]. Interestingly, ABCA3 is not only a drug-efflux pump but also a modulator of EV-release from B-cell lymphoma cells; furthermore, these exosomes shielded target cells from rituximab \[[@B147-cells-09-01141]\]. Similarly, trastuzumab was inefficient at inhibiting breast cancer cell proliferation when in the presence of HER2-carrying EVs \[[@B232-cells-09-01141]\]. Moreover, the activation of this receptor (which dimerizes with EGFR or HER3) stimulates EV production \[[@B232-cells-09-01141]\]. Curiously, the transfer of lncRNA small nucleolar RNA host gene 14 (SNHG14) by EVs shed by trastruzumab-resistant HER2+ breast cancer cells has also been reported to be a resistance mechanism to this antibody \[[@B185-cells-09-01141]\]. A comprehensive study in pancreatic ductal adenocarcinoma cell lines reported that an increase of miR-155 expression levels in cells transfected with pre-miR-155 caused an increase in the secretion of EVs and an increase in miR-155 expression levels on the released EVs content. Those EVs delivered miR-155 into other pancreatic ductal adenocarcinoma cancer cells, inducing gemcitabine-resistance in recipient cells \[[@B172-cells-09-01141]\].

A recent review has highlighted the role of RAB7A protein in cancer progression, EV secretion and EV-mediated cisplatin resistance in ovarian and cervical cancer cells \[[@B233-cells-09-01141]\]. The authors previously demonstrated that the downregulation of RAB7A increased cisplatin resistance in cervical cancer cell lines, which correlated with the increased production of EVs and reduction of cisplatin intracellular concentration, suggesting that chemoresistance resulted from a greater export of cisplatin through EVs \[[@B167-cells-09-01141]\]. Dorayappan et al. also reported that hypoxia increased the release of exosomes in ovarian cancer cells (through the activation of STAT3, up-regulation of RAB27A and down-regulation of RAB7, LAMP1/2 and NEU-1) and also increased the EV-mediated efflux of cisplatin from these cells \[[@B224-cells-09-01141]\].

4. Conclusions {#sec4-cells-09-01141}
==============

The vast majority of experimental evidence reviewed herein suggests a key role for EVs in favouring cancer hallmark traits throughout the distinct stages of cancer progression. Most importantly, we demonstrate that this cancer EVs signaling will ultimately favour the emergence of drug resistance. Thus, EVs are instrumental for the survival of resistant cancer clones which constitute a reservoir of minimal residual disease, responsible for the post-therapy refractory relapses in all human cancers.

Despite the scientific robustness, most experimental evidence on EVs was obtained from in vitro experiments and to a lesser extent in vivo models, thereby hampering the in-depth understanding of the cancer EVs signaling network with respect to clinical application. Although signifying an important proof-of-concept, these studies also seem to indicate that the EVs selective packaging and cargo is a highly dynamic process that relies on the experimental conditions and type of drug exposure. Thus, further studies in physiologically relevant models that recapitulate the TME throughout different stages of cancer progression will be a perquisite towards a more profound understanding of the tumor promoting EV signaling network. Unfortunately, most clinical research studies on EVs were based on very small sample sizes and require further validation in large clinical trials. This may justify in part why only few EV-based technologies are currently available for clinical cancer diagnosis/prognosis. It is now almost certain that EVs profiling could provide clinical guidance to predict tumor progression and unravel new strategies to regain control of disrupted EVs signaling network to our favour, either as EV-based drug delivery or as tumor EVs depletion strategies.

Taken together, a growing body of preclinical and clinical evidence reveals that EVs hold great potential as diagnostic cancer biomarkers or as naturally engineered carriers for targeted drug delivery, with some of these EV-based technologies being capable of reaching the market. Nevertheless, the main scientific challenges, including the development of highly sensitive single tumor-EV detection tools and the understanding of tumor EV trafficking and uptake, still need to be addressed to fully translate EV research into clinically reliable tools for cancer therapeutic applications.
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multidrug resistance-associated protein 1

MSC

Mesenchymal Stromal Cells

MVs

ectosomes or microparticles,

NEU1

lysosomal sialidase

NFATc3

Nuclear Factor Of Activated T Cells 3

NSCLC

non-small cell lung cancer

PAX2

paired box gene 2

PDCD4

programmed cell death 4

PDGFR

platelet-derived growth factor

PDK

Protein 3-phosphoinositide-dependent protein kinase

PD-L1

Programmed death-ligand 1

P-gp/MDR1/ABCB1

P-glycoprotein

PTPRZ1

Protein Tyrosine Phosphatase Receptor Type Z1

RAB7A

RAB7A

, Member RAS Oncogene Family

RBM11

RNA Binding Motif Protein 11

RhoA

member of the small GTPases family

RIG

\-

I

retinoic acid-inducible gene I

ROR

Receptor tyrosine kinase-like orphan receptor

ROS

reactive oxygen species

SBF2

\-

AS1

SBF2 antisense RNA 1

SNHG14

small nucleolar RNA host gene 14

SOD2

Superoxide dismutase 2

STAT3

Signal transducer and activator of transcription 3

TERF1

Telomeric Repeat Binding Factor 1

TERT

Telomerase reverse transcriptase

TGFBR1

Transforming Growth Factor Beta Receptor 1

TGF-β

transforming growth factor beta

TGM2

Transglutaminase 2

TIM-3

T-cell immunoglobulin and mucin-domain containing-3

TME

tumor microenvironment

TP53INP1

Tumor Protein P53 Inducible Nuclear Protein 1

TrpC5

Short transient receptor potential channel 5

TSG101

tumor susceptibility gene 101 protein

TSGA10

testis-specific gene antigen

TUFT1

Tuftelin 1

VE

\-

cadherin

vascular endothelial cadherin

VEGF

Vascular endothelial growth factor

VLDLR

Very Low Density Lipoprotein Receptor

XIAP

X-linked inhibitor of apoptosis protein

XRCC4

X-ray repair cross-complementing protein 4

ZEB1

\-

AS1

ZEB1 Antisense RNA 1

![Features of Extracellular Vesicle (EV) sub-populations. EVs are comprised of a heterogeneous group of lipid membrane enclosed vesicles produced by virtually all cells of the organism. EVs play a key role in intercellular communication to support homeostasis or cancer progression. Importantly, this heterogeneous group of EVs may include (**a**) exosomes with a size range between 30--120 nm that originate via the endosomal system, (**b**) microvesicles with a size range between 80--500 nm that derive from the outward budding of the cells' plasma membrane and even (**c**) apoptotic bodies that are secreted during the fragmentation of apoptotic cells. Upon secretion to the extracellular environment, exosomes and microvesicles have overlapping size range and share many markers (e.g., CD63, HSP70, CD9, CD81) while apoptotic bodies are characterized by an enrichment of phosphatidylserine on their surface. The similar features between exosomes and microvesicles make an accurate discrimination of EV origin very difficult when these subpopulations are mixed in complex biofluids. (**d**) The cancer-derived EVs are highly abundant in biological fluids such as blood, urine and saliva, and their surface immunophenotypic protein markers reflect the cell of origin. In clinical practice, (**e**) the detection of cancer-derived EVs in the biological fluids of patients can be explored for the disease diagnosis, while the EV cargo characterization also provides important clues on the disease prognosis.](cells-09-01141-g001){#cells-09-01141-f001}

![Impact of tumor-derived EVs on the acquisition and maintenance of cancer hallmarks traits. From the onset of tumor initiation, cancer-derived EVs modulate the phenotype of multiple recipient cell types to support tumor progression, metastasis and resistance to therapy. Indeed, many of the cancer cell clones may rely on the shedding of cancer-derived EVs to enable the (**a**) activation of several tyrosine kinase receptors and their downstream signalling pathways (e.g., MAP/ERK, PI3K/AKT and/or WNT). This cancer EV-mediated sustained proliferative signalling can be either autocrine or paracrine and confers tumor cells a key proliferative advantage. Moreover, in a synergistic event, (**b**) cancer-derived EVs also carry many oncoproteins and oncomiRs that when internalized by target recipient cancer cells enable them to override the growth suppressor signalling (e.g., through the reduction of PTEN and exacerbated expression ofMDM4 and/or cyclin D1 "oncogenic" splicing variants). Importantly, for successful tumor progression, tumor cells must acquire the ability to (**c**) evade immune destruction. Cancer-derived EVs serve this purpose as vectors for many immunosuppressive molecules, including galactin9 which binds TIM-3 on T cells inducing their death. Additionally, EV-associated TGF-β, PD-L1 and several miRs induce an immunosuppressive phenotype when internalized by immune cells. This includes the induction of a M2-like secretion profile on macrophages, CD8+ T cells anergy or stimulation of B and T cells to secrete a wide array of tumor supporting cytokines. (**d**) Cancer-derived EVs cargo may include TERT mRNA and/or other non-coding RNAs that induce the expression of telomerase in recipient fibroblasts and in other mutated cell clones, enabling a cancer stem cell phenotype with the acquisition of replicative immortality. (**e**) Cancer-derived EVs are also an important player for the perpetuation of chronic inflammation within the tumor microenvironment, which fosters multiple hallmark functions. Cancer-derived EVs carry several miRs including miR-27, -10b, -155-5p and other LncRNAs that target nearby fibroblasts, transforming them into cancer-associated fibroblasts (CAFs). In turn, CAFs secrete high amounts of IL-6 and TGF-β to the tumor microenvironment. Many of these cancer-derived EVs can also "educate" nearby Mesenchymal Stromal Cells (MSCs) to secrete large amounts of IL-8 and other immunosuppressive cytokines. Interestingly, this inflammatory microenvironment is prone to promote the formation of new blood vessels towards the tumor. (**f**) In fact, cancer-derived EVs cargo may also include VEGF, CRCX4 and EPHB2 and other epigenetic modulators, such as miR-103 as well as other lncRNAs, that increase the permeability of nearby blood vessels recruiting endothelial tip cells to promote angiogenesis. (**g**) Many of these EVs carry Matrix Metalloproteases (MMPs) and upon internalization by nearby cancer cells activate an Epithelial to Mesenchymal Transition (EMT) phenotype, inducing tumor cell invasion and metastasis to distant organs. Simultaneously, cancer-derived EVs will act on distant tissues to increase the expression of specific integrins and establish the pre-metastatic "niche". Noteworthy, the specific cancer-derived EVs tropism seems to be heavily reliant on the origin of the primary tumor. Moreover, the cancer-derived EVs cargo may in some cases include fragments of mutated DNA and other oncoproteins (**h**) that when transferred to other cancer cells will increase their genome instability and in turn generate high genetic diversity. Interestingly, (**i**) EVs may allow the horizontal transfer of drug resistance phenotype from drug resistant cancer cell clones to sensitive ones, mediated by cargo such as proteins (e.g., antiapoptotic proteins or drug efflux pumps), miRNAs, mRNAs, lncRNAs or lipids. (**j**) The same cancer drug-resistant derived EVs will induce a metabolic switch in recipient drug-sensitive cancer cells, reprogramming the energy metabolism towards glycolysis and increasing their levels of detoxifying enzymes such as Glutathione S-transferase P (GSTP1) granting a multidrug resistant phenotype in these cells.](cells-09-01141-g002){#cells-09-01141-f002}

![Impact of tumor-derived EVs in Cancer Therapy Resistance. EVs secreted from the few drug resistant (DR) cancer cells (on the left) or by normal cells within the tumor microenvironment (on the right) can contribute to exacerbate resistance in otherwise drug sensitive cancer cells (centre). (**a**) Exacerbated production of EVs by drug resistant cancer cell clones carrying on their surface the same tumour markers. These EVs will be targeted by certain monoclonal antibody-based therapeutics (e.g., trastuzumab, rituximab, etc.) and act as decoy receptors, lowering the availability of these targeted therapies to cancer cells. Additionally, in DR EVs (**b**) the drug efflux pumps may be inverted in the membrane of exosomes due to their biogenesis, when compared to their normal orientation in their donor cells. This can promote cytoplasmatic drug-influx into those EVs that will act as a drug efflux delivery system. EVs from a minor fraction of cancer drug resistant clones will (**c**) transfer functional drug efflux pumps (e.g., MDR1, MRP1, BCRP) to drug sensitive recipient cancer cells. This will enable recipient cells to efflux the drugs reducing the intracellular drug concentrations to sublethal levels. DR cancer cells can (**d**) promote the induction of anti-apoptotic pathways in recipient drug sensitive cells by transferring anti-apoptotic proteins (e.g., XIAPs, Bcl2, IAPs, Survivin, etc.). (**e**) Drug resistant clones also transfer TrpC5 protein through EVs to drug sensitive counterparts, activating the transcription factor NFATc3 and MDR1 gene expression. This will originate MDR1 efflux pumps production in recipient cells. (**f**) DR cell-derived EVs carry miR-31-5p that when internalized by drug sensitive counterparts promote down-regulation of MLH1 and consequently inhibit the mismatch repair system. This can lead to increased genomic instability and an aggressive phenotype in recipient cells. (**g**) DR cell-derived EVs have increased levels of GSTP1 mRNA/proteins that improve reactive oxygen species (ROS) detoxification in drug sensitive cells. Within the tumour microenvironment, stromal cells secrete EVs that will support a drug resistance phenotype in otherwise drug sensitive cancer cells. Indeed, (**h**) EVs from Cancer-associated Fibroblasts (CAFs) carry lncRNAs that will activate the β-catenin pathway in recipient cells inducing a cancer stem cell-like phenotype. Similarly, (**i**) EVs shed from Mesenchymal Stromal Cells (MSCs) have in their cargo miR-222/miR-223 and ZEB1 mRNA or (**j**) EVs secreted by monocytes carry miR155 that enable cancer resistance to several drugs (e.g., gemcitabine and cisplatin).](cells-09-01141-g003){#cells-09-01141-f003}

cells-09-01141-t001_Table 1

###### 

EVs cargo derived from different types of cancers with impact in the tumor hallmarks.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer Type from Released EVs                                                                   EVs Cargo                                                  Type of Study                         Refs
  ----------------------------------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------------------------------------------------------
  **Promoting cell proliferation and escape from apoptosis**                                                                                                                                       

  **Glioblastoma**                                                                                Splicing factor RBM11;\                                    In vitro, In vivo                     \[[@B48-cells-09-01141],[@B49-cells-09-01141]\]
                                                                                                  CLIC1                                                                                            

  **Melanoma**                                                                                    PDGFR-β                                                    In vitro                              \[[@B50-cells-09-01141]\]

  **Pancreatic cancer**                                                                           Zinc transporter ZIP4;\                                    In vitro, In vivo,\                   \[[@B51-cells-09-01141],[@B52-cells-09-01141],[@B53-cells-09-01141]\]
                                                                                                  miR-23b-3p; miR-222                                        Patients samples                      

  **Breast cancer**                                                                               miR-1246                                                   In vitro                              \[[@B54-cells-09-01141]\]

  **Cholangiocarcinoma**                                                                          miR-205                                                    In vitro                              \[[@B55-cells-09-01141]\]

  **Colon cancer**                                                                                DNp73 mRNA; miR-193a; mir-200b; lnRNA PVT1                 In vitro, In vivo                     \[[@B56-cells-09-01141],[@B57-cells-09-01141],[@B58-cells-09-01141],[@B59-cells-09-01141]\]

  **Thyroid cancer**                                                                              miR-222; miR-146b                                          In vitro                              \[[@B60-cells-09-01141]\]

  **Ovarian serous carcinoma**                                                                    miR-21                                                     In vivo, Patients samples             \[[@B61-cells-09-01141]\]

  **Acute leukemia**                                                                              miR-118, miR-116                                           In vivo, Patients samples             \[[@B62-cells-09-01141]\]

  **Gastric cancer**                                                                              lnRNA ZFAS1                                                In vitro                              \[[@B63-cells-09-01141]\]

  **Esophageal cancer**                                                                           miR-93-5p;\                                                In vitro, Patients samples            \[[@B52-cells-09-01141],[@B64-cells-09-01141]\]
                                                                                                  lncRNA ZEB1-AS1                                                                                  

  **Hepatocelular carcinoma**                                                                     lncRNA TUC339                                              In vitro                              \[[@B65-cells-09-01141]\]

  **Sustaining angiogenesis**                                                                                                                                                                      

  **Glioblastoma**                                                                                lnRNA CCAT2; lncRNA POU3F3; miR-21; CXCR4 receptor; VEGF   In vitro, In vivo                     \[[@B66-cells-09-01141],[@B67-cells-09-01141],[@B68-cells-09-01141],[@B69-cells-09-01141]\]

  **Head and neck squamous cell carcinoma**                                                       EPHB2                                                      In vitro, In vivo                     \[[@B70-cells-09-01141]\]

  **Hepatocellular carcinoma**                                                                    Vasorin; miR-103                                           In vitro, In vivo                     \[[@B71-cells-09-01141],[@B72-cells-09-01141]\]

  **Multiple myeloma**                                                                            piRNA-823                                                  In vivo                               \[[@B73-cells-09-01141]\]

  **Colon cancer**                                                                                miR-25-3p                                                  In vitro, In vivo                     \[[@B74-cells-09-01141]\]

  **Lung cancer**                                                                                 miR-14-3p; miR-145-5p; miR-23a                             In vitro                              \[[@B75-cells-09-01141],[@B76-cells-09-01141]\]

  **Ovarian carcinoma**                                                                           miRNA-141-3p                                               In vitro                              \[[@B77-cells-09-01141]\]

  **Oral cancer**                                                                                 miR-142-3p                                                 In vitro, In vivo                     \[[@B78-cells-09-01141]\]

  **Nasopharyngeal carcinoma**                                                                    miR-23a                                                    In vitro, Patients samples            \[[@B79-cells-09-01141]\]

  **Contributing to cancer cell invasion and metastasis**                                                                                                                                          

  **Cholangiocarcinoma**                                                                          miR-205-5p                                                 In vitro                              \[[@B55-cells-09-01141]\]

  **Breast cancer**                                                                               Caveolin-1                                                 In vitro                              \[[@B80-cells-09-01141]\]

  **Colon cancer**                                                                                Wnt5b; AREG                                                In vitro                              \[[@B81-cells-09-01141],[@B82-cells-09-01141]\]

  **Hepatocarcinoma**                                                                             CXCR4; SMAD3; miR-93; miR-103                              In Vitro; In vivo; Patient Samples    \[[@B72-cells-09-01141],[@B83-cells-09-01141],[@B84-cells-09-01141],[@B85-cells-09-01141],[@B86-cells-09-01141]\]

  **Gastric cancer**                                                                              miR-423-5p                                                 In vitro, In vivo; Patient samples    \[[@B87-cells-09-01141]\]

  **Prostate cancer**                                                                             miR-1246                                                   In vitro, In vivo; Patient samples    \[[@B88-cells-09-01141]\]

  **Glioblastoma**                                                                                miR-148a                                                   In vitro; Patient Samples             \[[@B89-cells-09-01141]\]

  **Ovarian Cancer**                                                                              miR-99a-5p                                                 In vitro                              \[[@B90-cells-09-01141]\]

  **Reprogramming energy metabolism**                                                                                                                                                              

  **Breast Cancer**                                                                               GSTP1; miR-122                                             In vitro; In vivo; Patient samples    \[[@B91-cells-09-01141],[@B92-cells-09-01141]\]

  **Transferring mutations**                                                                                                                                                                       

  **Glioblastoma**                                                                                fusion genes PTPRZ1-Met, EGFRvIII                          In vitro; In vivo                     \[[@B93-cells-09-01141],[@B94-cells-09-01141]\]

  **Melanoma**                                                                                    mRNA truncated Alk form                                    In vitro                              \[[@B95-cells-09-01141]\]

  **Colon cancer**                                                                                Mutant β-catenin                                           In vitro                              \[[@B96-cells-09-01141]\]

  **Ovarian cancer**                                                                              SMAD4                                                      In vitro                              \[[@B97-cells-09-01141]\]

  **Modulating the Tumor Microenvironment: evading immune response and promoting inflammation**                                                                                                    

  **Ovarian Cancer**                                                                              miR-1246, metabolic checkpoint molecular arginase-1        In vitro                              \[[@B98-cells-09-01141],[@B99-cells-09-01141]\]

  **Colon cancer**                                                                                miR-1246; miR-10b; CEACAM-family; Fas ligand               In vitro                              \[[@B100-cells-09-01141],[@B101-cells-09-01141],[@B102-cells-09-01141]\]

  **Liposarcoma**                                                                                 miR-25-3p; miR-921-3p                                      In vitro, In vivo, Patients samples   \[[@B103-cells-09-01141]\]

  **Glioblastoma**                                                                                miR-21, PD-L1                                              In vitro                              \[[@B104-cells-09-01141],[@B105-cells-09-01141]\]

  **Hepatocellular carcinoma**                                                                    lncRNA TUC339; miR-21                                      In vitro                              \[[@B106-cells-09-01141],[@B107-cells-09-01141]\]

  **Nasopharyngeal carcinoma**                                                                    miR-24-3p, galectin-9                                      In vivo, Patients Samples             \[[@B108-cells-09-01141],[@B109-cells-09-01141],[@B110-cells-09-01141]\]

  **Renal cell carcinoma**                                                                        Fas ligand                                                 In vitro                              \[[@B111-cells-09-01141]\]

  **Osteosarcoma**                                                                                miR-675                                                    In vitro                              \[[@B112-cells-09-01141]\]

  **Gastric Cancer**                                                                              miR-27a                                                    In vivo; Patient samples              \[[@B113-cells-09-01141]\]

  **Melanoma**                                                                                    miR-155-5p                                                 In vitro, In vivo                     \[[@B114-cells-09-01141]\]

  **Lung cancer**                                                                                 miR142-3p                                                  In vitro                              \[[@B115-cells-09-01141]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cells-09-01141-t002_Table 2

###### 

Intercellular transfer of drug resistant traits between resistant and sensitive cancer cells according to anti-cancer drug and cancer type.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Intercellular Transfer                     Specific EVs Cargo Transferred                  Anti-Cancer Drugs                     Cancer Type                                                        Cell Lines/\                                                                Refs
                                                                                                                                                                                                      Model/\                                                                     
                                                                                                                                                                                                      Patients Studies                                                            
  ------------------------------------------ ----------------------------------------------- ------------------------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------- ---------------------------------------------------
  **Drug-efflux pumps**                      MRP1/ABCC1                                      Multi-drug                            Leukemia,                                                          HL-60                                                                       \[[@B146-cells-09-01141]\]

  ABCA3                                      rituximab                                       B-cell lymphoma                       Su-DHL-4; Balm3; OCI-Ly1                                           \[[@B147-cells-09-01141]\]                                                  

  Pgp                                        Docetaxel\                                      Prostate, Breast\                     DU145 Tax-Sen/Tax-Res; 22Rv1 Doc-Res; MCF7\                        \[[@B148-cells-09-01141],[@B149-cells-09-01141],[@B150-cells-09-01141]\]\   
                                              \                                               \                                    MCF7/ADM vs MCF7/WT\                                               \[[@B151-cells-09-01141],[@B152-cells-09-01141],[@B153-cells-09-01141]\]\   
                                             Adriamycin\                                     Breast\                               MCF7;MG-63DXR30\                                                   \[[@B154-cells-09-01141],[@B155-cells-09-01141]\]\                          
                                             Doxorubicin\                                    Breast; Osteosarcoma\                 A2780;\                                                            \[[@B156-cells-09-01141]\]\                                                 
                                             Paclitaxel\                                     Ovarian;\                             BE (2)-C; VLB100; xenograft mouse models                           \[[@B157-cells-09-01141],[@B158-cells-09-01141]\]                           
                                              \                                              Neuroblastoma; Leukemia                                                                                                                                                              
                                             Multi-drug                                                                                                                                                                                                                           

  TrpC5                                      Adriamycin                                      Breast                                MCF7                                                               \[[@B152-cells-09-01141]\]                                                  

                                             ABCB1                                           Vincristine, cisplatin, doxorubicin   Oral squamous carcinoma                                            KBv200                                                                      \[[@B159-cells-09-01141]\]

                                             ABCG2                                           Mitoxantrone\                         Breast                                                             MCF7/MR; MCF7/FLV1000                                                       \[[@B160-cells-09-01141]\]
                                                                                             Topotecan                                                                                                                                                                            

  Imidazoacridinones\                        Breast                                          MCF7/MR; MCF7/FLV1000                 \[[@B161-cells-09-01141]\]                                                                                                                     
  methotrexate                                                                                                                                                                                                                                                                    

  **Apoptotic modulators**                   Survivin                                        Paclitaxel                            Triple-negative Breast                                             MDAMB231                                                                    \[[@B162-cells-09-01141],[@B163-cells-09-01141]\]

                                             Inhibitors of apoptosis proteins XIAP and IAP   Multi-drug                            Breast\                                                            MCF7\                                                                       \[[@B163-cells-09-01141]\]
                                                                                                                                   Chronic myeloid leukemia\                                          CML562\                                                                     
                                                                                                                                   Lungs                                                              A529                                                                        

  **Other Proteins**                         ATP1A1ATP1B3                                    cisplatin                             Squamous cell carcinoma                                            H314/H103                                                                   \[[@B164-cells-09-01141]\]

  TGM2                                       cisplatin                                       Squamous cell carcinoma               H314/H103                                                          \[[@B164-cells-09-01141]\]                                                  

  GSTP1p-STAT3                               5-fluoracil                                     Colorectal                            RKO                                                                \[[@B165-cells-09-01141]\]                                                  

  CLIC1                                      vincristine                                     Gastric                               SGC-7901                                                           \[[@B166-cells-09-01141]\]                                                  

                                             RAB7A                                           Cisplatin                             Ovarian\                                                           HeLa; A431; 2008 (and cisplatin-resistant counterpart cell lines)           \[[@B167-cells-09-01141]\]
                                                                                                                                   Cervical                                                                                                                                       

  **miRNAs**                                 miR-21                                          Multi-drug                            Chronic myeloid leukemia\                                          CMLK562\                                                                    \[[@B163-cells-09-01141]\]
                                                                                                                                   Breast                                                             MCF7                                                                        

  miR-96                                     Cisplatin                                       Lung                                  A549, H1299, MCF-7                                                 \[[@B168-cells-09-01141]\]                                                  

  miR-222                                    Adriamycin                                      Breast                                                                                                   \[[@B169-cells-09-01141]\]                                                  

  miR-155-5p, miR-542-3p, let-7 and miR-28   Docetaxel\                                      Triple-negative Breast                MCF10A                                                             \[[@B170-cells-09-01141]\]                                                  
                                             Doxorubicin                                                                                                                                                                                                                          

  miR-183-5p                                 Taxol\                                          Ovarian                               SKOV3, A2780, HEYA8                                                \[[@B171-cells-09-01141]\]                                                  
                                             Cisplatin\                                                                                                                                                                                                                           
                                             Multidrug                                                                                                                                                                                                                            

  miR-155                                    Gemcitabine                                     Pancreatic ductal adenocarcinoma      Panc1, MiaPaCa2, Colo-357 and PSN1 cell lines Patients samples,\   \[[@B172-cells-09-01141],[@B173-cells-09-01141]\]                           
                                                                                                                                   Murine xenograft model                                                                                                                         

  miR-221/222                                Tamoxifen                                       Breast                                MCF7                                                               \[[@B174-cells-09-01141]\]                                                  

  miR-19b                                    Oxaliplatin                                     Colorectal                            SW480                                                              \[[@B175-cells-09-01141]\]                                                  

  miR-145\                                   5-fluoracil                                     Colon cancer                          DLD-1                                                              \[[@B176-cells-09-01141]\]                                                  
  miR-34a                                                                                                                                                                                                                                                                         

  miR-31-5p                                  Sorafenib                                       Renal Cell Carcinoma                  786-0, ACHN, Patients samples                                      \[[@B177-cells-09-01141]\]                                                  

  miR-761                                    Pazopanib                                       Synovial Sarcoma                      SYO-1, HS-SYII, 1273/99, YaFuSS                                    \[[@B178-cells-09-01141]\]                                                  

  miR-1238                                   Temozolomide                                    Glioblastoma                          U251 cell line, patient samples                                    \[[@B179-cells-09-01141]\]                                                  

  miR-425-3p                                 Cisplatin                                       Non-small cell lung cancer            A549 cell line, Patients samples                                   \[[@B180-cells-09-01141],[@B181-cells-09-01141]\]                           

  miR-744                                    Sorafenin                                       Hepatocellular carcinoma              HepG2 cell line, Patients samples                                  \[[@B182-cells-09-01141]\]                                                  

  miR-100-5p                                 Cisplatin                                       Lung                                  A549                                                               \[[@B183-cells-09-01141]\]                                                  

  **mRNAs**                                  DNMT1 mRNA                                      Cisplatin                             Ovarian cancer                                                     Xenograft mouse model                                                       \[[@B184-cells-09-01141]\]

                                             GSTP1 mRNA                                      Adriamycin                            Breast                                                             MCF7                                                                        \[[@B91-cells-09-01141]\]

  **lncRNAs**                                lncSNHG14                                       Trastruzumab                          HER2-positive Breast                                               HER2-positive SKBR-3,\                                                      \[[@B185-cells-09-01141]\]
                                                                                                                                                                                                      HER2-positive BT474                                                         

  linc-ROR\                                  Sorafenib\                                      Hepatocellular carcinoma              HepG2, Hep3B, PLC/PRF-5 and Huh-7                                  \[[@B186-cells-09-01141],[@B187-cells-09-01141]\]                           
  linc-VLDLR                                 Doxorubicin                                                                                                                                                                                                                          

  linc-VLDLR-ABCG2                           Multidrug                                       Esophageal cancer                     Eca109 cell line, Patients samples                                 \[[@B188-cells-09-01141]\]                                                  

  lncARSR                                    Sunitinib                                       Renal Cell carcinoma                  786-O, ACHN, xenograft mouse models                                \[[@B189-cells-09-01141]\]                                                  

  lncHOTTIP                                  Cisplatin                                       Gastric                               Xenograft mouse models,\                                           \[[@B190-cells-09-01141]\]                                                  
                                                                                                                                   Patients samples                                                                                                                               

  lncHNF1A-AS1                               Cisplatin                                       Cervical cancer                       HeLa                                                               \[[@B191-cells-09-01141]\]                                                  

  linc-SBF2-AS1                              Temozolomide                                    Glioblastoma                          U87, LN229, A172, T98, U251, Patients samples                      \[[@B192-cells-09-01141]\]                                                  

  linc-AGAP2-AS1                             Trastuzumab                                     HER2-positive Breast                  HER2-positive SKBR-3, HER2-positive BT474                          \[[@B193-cells-09-01141]\]                                                  

  **Lipids**                                 Multiple phospholipids                          Gefitinib                             Lung                                                               PC9R                                                                        \[[@B194-cells-09-01141]\]

  Acid Sphingomyelinase                      Melphalan\                                      Multiple myeloma                      JJN3, LP1, OPM2, U266                                              \[[@B195-cells-09-01141]\]                                                  
                                             Bortezomib                                                                                                                                                                                                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: These authors equally contributed to this work.
